With continued global expansion, NEXT Oncology is one of the world’s largest Phase 1 Cancer Trial organizations.
(SAN ANTONIO, TX) July 29, 2025 –– NEXT Oncology has expanded its services to Brazil through a strategic partnership with Onco D’Or Oncologia S.A., the subsidiary of Rede D’Or São Luiz (RDOR3) for oncology services, and IDOR – Instituto D’Or de Pesquisa e Ensino, a non-profit organization for science research, education and innovation. Under the guidance of Dr. Paulo Marcelo Hoff and Dr. Mirella Nardo, Oncologia D’Or will now offer patients the opportunity to participate in Phase 1 clinical trials as part of the global NEXT Oncology network.
Dr. Hoff is a Full Professor of Clinical Oncology at the University of São Paulo and the President of Rede D’Or Oncology. He completed his clinical postdoctoral fellowship in Hematology and Oncology at The University of Texas MD Anderson Cancer Center, where he was also named Professor of the Year in 2000. He is a former ASCO Board Member (2013–2018) and a FASCO honoree, in recognition of his outstanding volunteer service and leadership in the field of oncology.
Dr. Nardo is a clinical oncologist specialized in early-phase trials. She completed a clinical research fellowship in Investigational Cancer Therapeutics at MD Anderson Cancer Center, where she served as Chief Fellow. She currently holds a faculty position at Oncologia D’Or.
With locations in San Antonio, Austin, Dallas, and Houston, Texas; Arlington, Virginia; Barcelona and Madrid, Spain; and now São Paulo, NEXT Oncology has treated more than 1,000 patients per year—cementing its position as one of the leading Phase 1 clinical trial centers in the world.
“Our mission is to cure cancer by accelerating the development of new and innovative medicines for patients whose current therapies are no longer working,” Dr. Anthony Tolcher, NEXT Oncology’s CEO and Founder stated. “This partnership with Rede D’Or’s oncology and research companies represents an important step forward in our global expansion—bringing the most promising new cancer therapies to patients worldwide and allowing our sponsors to reach patients in Brazil and South America.”
“NEXT Oncology’s exceptional reputation for advancing the science of cancer treatment is unmatched,” said Dr. Hoff. “Together, we will bring transformative, cutting-edge therapies to patients in Brazil—offering new hope where it’s needed most.”
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT Oncology is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT Oncology unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.